Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 9/20 | 0.52 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21677403 | 0.87 | NLRP3 (0.48) | NLRP3SLC18A2TP53THRBMAPT | |
| SCHEMBL21677208 | 0.86 | NLRP3 (0.67) | NLRP3SLC18A2TP53THRBMAPT | |
| SCHEMBL21677400 | 0.81 | NLRP3 (0.66) | NLRP3KCNH2 | |
| SCHEMBL21677223 | 0.78 | NLRP3 (0.65) | NLRP3SLC18A2TP53THRBMAPT | |
| SCHEMBL21677268 | 0.77 | NLRP3 (0.46) | NLRP3SLC18A2TP53THRBMAPT | |
| SCHEMBL21677267 | 0.75 | NLRP3 (0.61) | NLRP3SLC18A2TP53KCNH2 | |
| SCHEMBL25360986 | 0.73 | NLRP3 (0.48) | NLRP3SLC18A2TP53THRBMAPT | |
| SCHEMBL21632140 | 0.72 | NLRP3 (0.82) | NLRP3SLC18A2TP53THRBKCNH2 | |
| SCHEMBL21632287 | 0.72 | NLRP3 (0.66) | NLRP3SLC18A2THRBKCNH2 | |
| SCHEMBL21677312 | 0.72 | NLRP3 (0.33) | NLRP3SLC18A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168012-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2024-12-17 | — | — | US | disclosed |
| EP-3827008-B1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| CN-112424207-B | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20210308140-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| US-20210308140-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| WO-2020021447-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168012-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | NLRP3 1/4885SLC18A2 4539/4885TP53 1469/4885 |
| US-20210308140-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | NLRP3 1/4885SLC18A2 4515/4885TP53 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.